Biotechnology Value Fund — Full Portfolio

Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.

AI & Machine LearningBiotechDeep TechPortland, US

SMSean McClain(Executive Officer)inPhil Barish(Executive Officer)inZachariah Jonasson(Chief Financial Officer and Chief Business Officer)SWShelby Walker(Chief Legal Officer)inRSRansi Somaratne(Chief Medical Officer)ABAndreas Busch(Chief Innovation Officer)in

Co-investorsDADas & Co.OROregon Venture FundPHPhoenix Venture PartnersTATachyon VenturesTATau VenturesCACasdin Capital+2 more

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.

BiotechHealthtechMenlo Park, US

Joseph S. Zakrzewski(Co-Founder & Director)EEEric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)SCSanjay Chanda(Chief Development Officer)inLOLucy O. Day(Chief Financial Officer)in

Co-investorsADAdjuvant CapitalBIBioRock VenturesFLFlucas VenturesMOMountain Group CapitalRARA CapitalHAHatteras Venture Partners

AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders.

BiotechSan Diego, US

RHRobert Hoffman(Executive Officer)inMarco Londei(Executive Officer)inHSHamza Suria(Executive Officer, Director)inDFDaniel Faga(President, CEO, and Director)inCMChristopher Murphy(CFO)

BoardCarol Gallagher(Director)

Co-investorsBIBioBritFRFrazier Life SciencesNONorwest Venture PartnersNONovo Holdings

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

EBElizabeth Buck(Chief Scientific Officer)Brent Hatzis-Schoch(Chief Operating Officer and General Counsel)Sergey Yurasov(Chief Medical Officer)Melanie Morrison(Chief Development Officer)

Co-investorsLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)NENextech InvestNSNSG VenturesRARA Capital+3 more

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

MKMary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)JMJennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNANadim Ahmed(President and Chief Executive Officer)in

Co-investorsFOForesite CapitalNENextech InvestOROrbiMed

Foghorn Therapeutics is a clinical-stage biotech developing chromatin-targeted cancer drugs via its Gene Traffic Control platform, including a candidate co-developed with Eli Lilly.

AGAdrian Gottschalk(President and Chief Executive Officer)

Co-investorsFLFlagship PioneeringDEDeerfield Management Company

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

PSPaul Stone(Executive Officer)inYujiro S. Hata(President, Chief Executive Officer and Director)

BoardTSTimothy Shannon(Director)inJDJohn Diekman(Director)inTRTerry Rosen(Director)JSJeffrey Stein(Director)

Co-investors5A5AM VenturesCACanaan PartnersNENextech InvestWUWuXi Healthcare Ventures

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

NMNello Mainolfi(Founder)inBBBruce Booth(Chair)in

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsBABain Capital Life SciencesBEBessemer Venture PartnersHAHatteras Venture PartnersMRMRL Ventures Fund+5 more

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)inCLCyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesFOForesite CapitalLILightspeed Venture PartnersRARA CapitalLOLogos+1 more

ShouTi Inc. is a clinical-stage biopharmaceutical company developing oral small molecule drugs targeting G-protein coupled receptors to treat chronic diseases including obesity, type 2 diabetes, and cardiovascular conditions.

BiotechSouth San Francisco, US

RSRaymond Stevens(Director)Ramy Farid(Director)Jessica Lifton(Director)Ting Xie(Director)Daniel Auerbach(Director)Cuiping Gu(Director)

Co-investorsF-F-Prime Capital

Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.

BiotechHealthtechMedical DevicesAustin, US

Shanshan Xu(Founder & Chief Executive Officer)inHJHelmut Jeggle(Co-Founder)inThang Ho(Chief Development Officer)inCrystal MacKay(Chief Operating Officer)in

Co-investorsININCE CapitalRARA CapitalJAJanus Henderson InvestorsREREDMILESASalvia

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

KEKevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)GBGurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

Co-investorsMBMBX CapitalALAllied Venture PartnersAMAmboy Street VenturesAUAurum Venture PartnersBEBeni Venture CapitalCLCleo Capital+14 more

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.

BiotechHealthtechMedical DevicesLondon, GB

DJDr Jeff Moore(Founder & CEO)

Co-investorsATAtlas VentureCACanaan PartnersPRProspect Venture PartnersOXOxford Technology Management

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureFOForbionLILightspeed Venture PartnersREResearch Corporation TechnologiesTCTCG Crossover

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(MD)KLKuo-Shyan Lin(PhD)DPDavid Perrin(PhD)

Co-investorsANAndreessen HorowitzDEDelos CapitalGEGeneral CatalystLILightspeed Venture PartnersLOLongitude CapitalLULumira Ventures+8 more

BiotechSeattle, US

Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJPJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)

Co-investorsDEDecheng CapitalFRFrazier Life SciencesOROrbiMed

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsAMaMoonDEDelos CapitalRARA CapitalSOSoleus Capital

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

AFAdam Friedman(Chief Executive Officer)inAFAndrew Fedder(Executive Officer, Director)inBPBrian Piper(Executive Officer, Director)in

Co-investorsATAtlas VentureLILightspeed Venture PartnersVIVida VenturesOMOmega FundsTETenmileABAbingworth

Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.

BiotechHealthtechPhiladelphia, US

KOKaryn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)

BoardElizabeth Anderson(Director)Bruce Peacock(Director)

Co-investorsAVAvego BioScience CapitalHEHealthCapAGAgent CapitalCOCowen Healthcare InvestmentsJOJohnson & Johnson Innovation – JJDCNONorthpond Ventures

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardACAlexandra Cantley(Director)inSakae Asanuma(Director)inBMBriggs Morrison(Executive Officer, Director, Promoter)inIMIrena Melnikova(Director)in

Co-investorsMPMPM BioImpactPFPfizer Venture InvestmentsMIMirae Asset Venture InvestmentPFPfizer VenturesPOPolaris PartnersTATaiho Ventures, LLC

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

NTNenad Tomasevic(Chief Executive Officer, Founder)

BoardIvan Trifunovich(Director)John Wesley(Director)

Co-investors8V8VCAIAisling CapitalMIMission Bay CapitalMIMission BiocapitalOLOlive Tree CapitalSRSR One Capital Management+3 more

Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.

AI & Machine LearningBiotechMedical Devices

Steven Perrin(President and Chief Scientific Officer)

Co-investorsJDJDRF T1D FundNENewpath Partners

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)DLDavid LiuinASAlan Saghetelian

Co-investorsNENewpath PartnersCRCRV (Charles River Ventures)NENextech InvestRARaptor GroupSASamsara BioCapitalCACasdin Capital+1 more

Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.

BiotechMedical Devices

Co-investorsEUEuropean Investment BankANAndera PartnersCLClaret Capital PartnersNENew Enterprise Associates (NEA)SASamsara BioCapitalSOSofinnova Partners+1 more

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

DKDavid King(Co-Founder & CSO)inMFMaria Fardis(CEO)inCCCadmus C. Rich(Chief Medical Officer)inESElaine Stracker(General Counsel)in

Co-investorsALAlta PartnersCACatalio Capital Management, LPDCDC Investment PartnersLOLongitude CapitalLOLongwood FundCACatalio Capital Management+2 more

Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.

BiotechHealthtech

Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)MNMichael Naill(Senior Vice President, Process and Product Development)in

Co-investorsBABain Capital Life SciencesTHThird Rock VenturesGVGV (Google Ventures)

Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.

Deep TechEnergyHardware

Michael Gorman(Founder)in

Co-investorsFOFoothill VenturesACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesCOCommodore CapitalGVGV (Google Ventures)+2 more

BiotechBoston, US

DDDarlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDMDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in

BoardChau Khuong(Director)inChristina Takke(Director)Steven Prelack(Director)

Co-investorsFRFrazier Life SciencesOROrbiMed

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)

BoardMKMaha Katabi(Director)inPNPerry Nisen(Executive Officer, Director)inMFMaria Fardis(Director)inRJRajul Jain(Director)in

Co-investorsLOLongitude CapitalSOSofinnova VenturesVIVida VenturesFRFrazier Life Sciences

BiotechFremont, US

AVAvanish Vellanki(Executive Officer)in

Co-investorsJAJanus Henderson InvestorsSASamsara BioCapital

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

ARAaron Ring(Executive Officer, Director)inBMBeatrice McQueen(Chief Operating Officer)inSRSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)HUHirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsCOConnecticut InnovationsPFPfizer Venture InvestmentsSRSR One Capital ManagementAXAxial VCRORock Springs CapitalSASamsara BioCapital

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)

BoardAGArjun Goyal(Director)inOtello Stampacchia(Director)inFDFrancesco Draetta(Director)in

Co-investorsANAndreessen HorowitzVIVida VenturesABabrdn plcFOForesite CapitalHIHillhouse InvestmentOMOmega Funds+1 more

Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.

AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande

Maran Vedamanikam(CEO and Manager)

Co-investorsSASamsung NextANAndreessen HorowitzWNWndrCoALAlexandriaCACasdin CapitalFOFonds de solidarité FTQ+5 more

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder)DKDaniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)

BoardJRJosh Resnick(Director)in

Co-investorsANAndreessen HorowitzGVGV (Google Ventures)RARA CapitalSOSoftBank Vision FundVEVersant VenturesCACasdin Capital+2 more